Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients

BMC Cancer

Table 1 Gender, age, and serum CCL2 levels of the study subjects. (Individual patient data is shown in Additional file 1: Table S1)

	Number of Patients	Gender		Age	Serum CCL2 (pg/ml)
	Number of Patients	Women	Men	Age	Serum CCL2 (pg/ml)
Unexposed (no apparent disease)	41	10	31	56.0 ± 20.0	275.2 ± 98.2
Possibly Exposed (no apparent disease)	356	33	323	68.7 ± 8.3	307.5 ± 117.7
Mesothelioma (all patients)	50	5	45	72.5 ± 8.6	421.3 ± 295.1^a,b
Mesothelioma (stage 1 patients)	12	0	12	72.8 ± 9.1	289.9 ± 115.4
Mesothelioma (stage 2 patients)	5	0	5	75.6 ± 7.1	281.0 ± 111.2
Mesothelioma (stage 3 patients)	14	1	13	74.3 ± 10.7	486.0 ± 333.4^c,d
Mesothelioma (stage 4 patients)	19	4	15	70.2 ± 6.8	493.5 ± 346.7^c,d

^aDifferent from the Unexposed (no apparent disease) group at p < 0.01
^bDifferent from the Possibly Exposed (no apparent disease) group at p < 0.05
^cDifferent from the Unexposed (no apparent disease) and the Possibly Exposed (no apparent disease) groups at p < 0.001
^dDifferent from the Mesothelioma (stage 1 patients) group at p < 0.01

ISSN: 1471-2407